The impact of digital breast tomosynthesis on screening performance and screen-detected cancers appears to generalize beyond trials and academic centers to the community setting.
Digital breast tomosynthesis screening is associated with increased detection of invasive breast cancer and younger age at time of cancer diagnosis compared with digital mammography, according to a study recently published in the American Journal of Roentgenology.
The retrospective study also found that invasive cancers detected with digital breast tomosynthesis were of similar histologic and molecular subtype as those detected by digital mammography but were more frequently low grade and node negative.
“Our study was performed in a community setting,” Shruthi Ram, M.D., of The Warren Alpert Medical School of Brown University in Rhode Island, told Diagnostic Imaging. “Thus, current insights into the impact of digital breast tomosynthesis on screening performance and screen-detected cancers appear to generalize beyond trials and academic centers to the community setting.”
Data were retrospectively retrieved for all screening mammograms performed by digital breast tomosynthesis and digital mammography at four outpatient private practice facilities from Jan. 1, 2012 to July 10, 2019. Examinations were interpreted by one of 26 radiologists and further detailed information was recorded for all screen-detected cancers from radiology and pathology reports.
A total of 310 cancers were detected from 47,096 screening digital breast tomosynthesis examinations and 83,200 screening digital mammography examinations. Digital breast tomosynthesis, compared with digital mammography, had a higher cancer detection rate (3.4 vs 1.8 per 1000 screenings; P <.001).
The mean age of cancer detection was three years younger for digital breast tomosynthesis than digital mammography (61 vs 64 years; P =.02) and a higher percentage of cancers were detected in patients aged 40-49 for digital breast tomosynthesis. Meanwhile, cancers detected with digital breast tomosynthesis, compared with digital mammography, were more often invasive (85.1% vs 72.5%; P =.006), grade 1 (27.9% vs 17.8%; P =.04) and node negative (92.2% vs 78.4%; P =.02).
“While our digital breast tomosynthesis recall rate was initially higher than digital mammography, this improved with subsequent rounds of screening,” Ram said
“Digital breast tomosynthesis utilization for screening has been increasing in the U.S.,” she said, adding that “while further studies with detailed analyses of cost to benefit ratio of digital breast tomosynthesis screening are needed, the findings from our study show promise for potentially justifying the widespread use of digital breast tomosynthesis in the community.”
Further studies are also needed on the effect of digital breast tomosynthesis on interval cancer rate and breast cancer mortality outcomes, Ram added.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.